These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Transcriptional activation of endogenous Oct4 via the CRISPR/dCas9 activator ameliorates Hutchinson-Gilford progeria syndrome in mice. Kim J; Hwang Y; Kim S; Chang Y; Kim Y; Kwon Y; Kim J Aging Cell; 2023 Jun; 22(6):e13825. PubMed ID: 36964992 [TBL] [Abstract][Full Text] [Related]
11. A Safer Path to Cellular Rejuvenation: Endogenous Oct4 Activation via CRISPR/dCas9 in Progeria Mouse Models. Hu D; Borgne EL; Meinl R Cell Reprogram; 2023 Aug; 25(4):136-138. PubMed ID: 37327373 [TBL] [Abstract][Full Text] [Related]
12. Unveiling epigenetic regulation in cancer, aging, and rejuvenation with in vivo reprogramming technology. Sogabe Y; Seno H; Yamamoto T; Yamada Y Cancer Sci; 2018 Sep; 109(9):2641-2650. PubMed ID: 29989289 [TBL] [Abstract][Full Text] [Related]
18. In vivo reprogramming for tissue regeneration and organismal rejuvenation. Taguchi J; Yamada Y Curr Opin Genet Dev; 2017 Oct; 46():132-140. PubMed ID: 28779646 [TBL] [Abstract][Full Text] [Related]
19. In Vivo Transient and Partial Cell Reprogramming to Pluripotency as a Therapeutic Tool for Neurodegenerative Diseases. Tamanini S; Comi GP; Corti S Mol Neurobiol; 2018 Aug; 55(8):6850-6862. PubMed ID: 29353456 [TBL] [Abstract][Full Text] [Related]
20. Fibroblast rejuvenation by mechanical reprogramming and redifferentiation. Roy B; Yuan L; Lee Y; Bharti A; Mitra A; Shivashankar GV Proc Natl Acad Sci U S A; 2020 May; 117(19):10131-10141. PubMed ID: 32350144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]